sb 202190 has been researched along with seryl-leucyl-isoleucyl-glycyl--arginyl-leucinamide in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Collier, ME; ElKeeb, AM; Ettelaie, C; Maraveyas, A | 1 |
1 other study(ies) available for sb 202190 and seryl-leucyl-isoleucyl-glycyl--arginyl-leucinamide
Article | Year |
---|---|
Accumulation of tissue factor in endothelial cells induces cell apoptosis, mediated through p38 and p53 activation.
Topics: Amino Acid Substitution; Apoptosis; bcl-2-Associated X Protein; Breast Neoplasms; Cardiovascular Diseases; Cell Line, Tumor; Cell-Derived Microparticles; Cells, Cultured; Coronary Vessels; Cyclin D1; Endothelial Cells; Enzyme Activation; Female; Gene Expression Regulation; Genes, Reporter; Humans; Imidazoles; MAP Kinase Signaling System; Oligopeptides; p38 Mitogen-Activated Protein Kinases; Pyridines; Recombinant Fusion Proteins; RNA Interference; RNA, Messenger; RNA, Small Interfering; Thromboplastin; Transfection; Tumor Suppressor Protein p53 | 2015 |